Skip to main content
Clinical Trials/CTRI/2026/02/102925
CTRI/2026/02/102925Not yet recruitingPhase 1

Comparison of post-operative cycloplegia, miotics, and no treatment after Minimally Invasive Glaucoma Surgery: A Randomized Controlled Trial.

Not provided1 site in 1 country60 target enrollmentStarted: February 17, 2026Last updated:

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Enrollment
60
Locations
1
Primary Endpoint
The change of PAS from baseline

Study Overview

Brief Summary

Minimally Invasive Glaucoma Surgeries (MIGS) have developed in recent years. These procedures are characterized by ab-interno microincisions, minimal trauma, a high safety profile, high efficacy, and fast recovery.

Although minimally invasive glaucoma surgeries (MIGS) have made significant advancements, they are not without failures. Studies indicate that failure rates for various MIGS procedures can range from 20% to 40%. (9-11) Several factors contribute to these failures, including postoperative intraocular pressure (IOP) spikes and heightened responses to steroids. Additionally, the formation of peripheral anterior synechiae (PAS) may lead to increased IOP after surgery, which can further raise the failure rates of these procedures.

Our study aims to investigate whether the use of cycloplegic drops postoperatively, which keeps the lens-iris diaphragm positioned posteriorly, can reduce the formation of PAS and lower the failure rates in patients undergoing MIGS.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant Blinded

Eligibility Criteria

Ages
3.00 Month(s) to 80.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Any diagnosed case of glaucoma, undergoing MIGS during the study period.

Exclusion Criteria

  • Any patient with blood dyscrasia.

Outcomes

Primary Outcomes

The change of PAS from baseline

Time Frame: Three months

The extent of PAS (in clock hours)

Time Frame: Three months

IOP and correlation to PAS

Time Frame: Three months

Secondary Outcomes

  • Intraocular Pressure(3 months)
  • Reduction in antiglaucoma meds(3 months)

Investigators

Sponsor
Not provided
Responsible Party
Principal Investigator
Principal Investigator

Sushmita Kaushik

Post Graduate Institute of Medical Education and Research, Chandigarh

Study Sites (1)

Loading locations...

Similar Trials

Medications for best results after MIGS | Clinical Trial